Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Apatinib plus paclitaxel-platinum versus paclitaxel-platinum for first-line advanced cervical cancer
ChiCTR1800018232Phase 2Recruiting
- Sponsor
- Sun Yat-sen University Cancer Center
- Start
- Aug 2018
- Modality
- Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised trial of Rivoceranib, paclitaxel, cisplatin and carboplatin in Cervical Cancer (CC) (2 arms), sponsored by Sun Yat-sen University Cancer Center. Primary endpoint: Progression-free survival. Started Aug 2018; status: recruiting.
02
Drugs
Rivoceranibpaclitaxelcisplatincarboplatin
03
Conditions
Cervical Cancer (CC)
Beyond the preview
Go deeper on ChiCTR1800018232.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR1800018232.